A multistep approach to single nucleotide polymorphism–set analysis: an evaluation of power and type I error of gene-based tests of association after pathway-based association tests
© The Author(s). 2016
Published: 18 October 2016
The aggregation of functionally associated variants given a priori biological information can aid in the discovery of rare variants associated with complex diseases. Many methods exist that aggregate rare variants into a set and compute a single p value summarizing association between the set of rare variants and a phenotype of interest. These methods are often called gene-based, rare variant tests of association because the variants in the set are often all contained within the same gene. A reasonable extension of these approaches involves aggregating variants across an even larger set of variants (eg, all variants contained in genes within a pathway). Testing sets of variants such as pathways for association with a disease phenotype reduces multiple testing penalties, may increase power, and allows for straightforward biological interpretation. However, a significant variant-set association test does not indicate precisely which variants contained within that set are causal. Because pathways often contain many variants, it may be helpful to follow-up significant pathway tests by conducting gene-based tests on each gene in that pathway to narrow in on the region of causal variants. In this paper, we propose such a multistep approach for variant-set analysis that can also account for covariates and complex pedigree structure. We demonstrate this approach on simulated phenotypes from Genetic Analysis Workshop 19. We find generally better power for the multistep approach when compared to a more conventional, single-step approach that simply runs gene-based tests of association on each gene across the genome. Further work is necessary to evaluate the multistep approach on different data sets with different characteristics.
As next-generation sequencing prices decrease, the demand for statistical methods to interpret the wealth of new data generated by this technology has risen dramatically. The field is now moving past single-marker tests of association for common variants using genome-wide association studies, instead expanding the search to include rare variants. The analysis of rare variants presents unique statistical issues, such as very low power and high multiple testing penalties for single-marker association tests. In recent years numerous methods have been developed that aggregate rare variants into sets, often genes, and run a gene-based test of association to compute a single p value for the entire gene. These methods reduce multiple testing penalties and have been shown to increase power in detection of rare variants [1–4].
Gene-based tests of association, while successful in identification of genes with moderate to strong effect sizes, cannot always detect genes with weak effect sizes. Because of multiple testing penalties and lower power to detect genes with weak effects, these genes will often go undetected . By aggregating genes into functionally associated gene sets, or biological pathways, we can reduce the number of tests needed to analyze all the information and, thus, decrease multiple testing penalties. Testing pathways for association with a phenotype of interest may also increase power by aggregating independent associations across a set of genes. In addition, the pathway-based association testing approach allows for the incorporation of biological information and a straightforward, biological interpretation.
Traditional pathway-based association testing involves 2 stages: (a) generate statistics for each gene in a pathway, and (b) aggregate separate gene-level statistics into a single statistic for the pathway . More recently, single-stage association tests have been developed. These approaches are similar to gene-based tests of association in that they group variants into sets and compute a single statistic for the entire pathway. Some groups have considered direct application of tests originally designed as gene-based tests as single-stage pathway tests . Prior research suggests that single-and 2-stage pathway-based association tests will each be optimal under distinct genetic architectures .
Although pathway-based association tests can offer improvements in power for detecting association with phenotypes of interest, a significant pathway-based association test does not indicate which of the variants or genes within that pathway are associated with the disease status. Recently, Juraeva et al.  proposed a multistep approach for variant-set analysis to address this limitation (first Global Test  to identify pathways, then FORGE [Functional element Overlap analysis of the Results of Genome Wide Association Study Experiments]  to identify potentially causal genes). However, the Juraeva et al. method has some limitations: (a) it requires a replication data set, (b) is limited in the choice of test statistic at the gene or pathway level, and (c) is not directly applicable to family-based studies. Family-based studies have many advantages, including potentially increased power in rare variant identification . Unfortunately, most pathway-based association methods are unable to directly account for complex pedigrees [10, 11] or cannot account for covariates [9, 12].
In this paper, we propose a novel approach to address existing limitations. In particular, we propose a multistep pathway-based association test for family-based data on complex pedigrees. For the first step we apply a single-stage pathway-based test of association and for the second step we apply commonly-used gene-based test of association to each gene in a significant pathway. We compare our proposed multistep approach to the performance of two commonly used gene-based tests of association (also adapted for family data). In particular, we evaluate the power and type I error of the single- versus multistep association testing approaches using simulated data on blood pressure from Genetic Analysis Workshop 19 (GAW19). We show that our proposed multistep testing approach offers improvements in power, further motivating the application of pathway-based tests of association.
GAW19 provided genome sequence data (for odd-numbered autosomes), simulated phenotypes, and covariates for 849 individuals from large Mexican American families . Systolic blood pressure (SBP), diastolic blood pressure (DBP), hypertension status, sex, age, smoking habits, and blood pressure medication information is provided at each of 3 examination periods in the simulated data. The simulated data was used in this analysis in order to evaluate type I error and power. To account for the effect of blood pressure medication on blood pressure levels, we made a standard adjustment by adding 10 mmHg and 5 mmHg to the SBP and DBP measurements, respectively, for subjects taking blood pressure medication at each examination [14, 15]. We also calculated the mean arterial pressure (MAP), our response variable of interest, for each individual using the standard formula (MAP = 2/3 DBP + 1/3 SBP). To collapse longitudinal phenotype and covariate information, average age, SBP, DBP, and MAP were calculated and smoking habit was collapsed into a binary variable for whether the subject smoked at least once during the 3 examination periods.
Creation of sets of variants (genes and pathways)
Settings for creation of synthetic pathways
Number of genes
Number of pathways
We identified 2 commonly used gene-based tests of association  that account for complex pedigree structure, a quantitative response variable, and are easily implemented using a published R package. One of these methods is a sequence kernel association test (SKAT)–like, or variance component, test of association and the other method is a burden test in the spirit of Combined Multivariate and Collapsing (CMC). Hereafter, we refer to these methods as VC test and Burden test . VC test is a weighted sum of single-variant score tests computed as ∑ j = 1 m w j U j 2 , where j = 1,…, m is an index across m variants, w j is a weight, and U j is the score statistic for the association between phenotype and variant j. The skatMeta function was used with default (beta) weights. Burden test regresses the phenotype on a weighted sum of genotypes within each set by computing ∑ j = 1 m w j U j . The burdenMeta function was used with default weights (w j = 1). Both VC test and Burden test test for association between a quantitative trait and sets of rare variants, while also accounting for covariates. It should be noted that both tests employ a theoretical, rather than empirical, estimation of the kinship matrix.
Application of tests
We applied VC test and Burden test to the GAW19 data in 2 distinct ways.
We applied both a SKAT-like  (VC test ) and a CMC-like  (Burden test ) to all 245 genes containing at least 1 causal variant as implemented in a publicly available R package . These gene-based approaches test the null hypothesis that no variant contained within the gene is associated with the disease phenotype (in our case, MAP).
First, VC test was applied to each of the 82 pathways, treating the pathways as very large sets of variants to test if the pathway shows evidence that at least 1 variant is associated with the phenotype. For each pathway flagged as significant, we then apply VC test to each gene within the pathway, separately, in order to identify significant genes within the pathway. This combination of tests is referred to in the remainder of the paper as the VC test -VC test approach. We also looked at 3 other combination of tests: VC test at the pathway level, followed by Burden test at the gene level (VC test -Burden test ); Burden test at the pathway level, followed by VC test at the gene level (Burden test -VC test ); and Burden test at both the pathway and gene level (Burden test -Burden test ).
Estimation of power and type I error
To get empirical estimates for power and type I error of each method, tests were run on each of the 200 simulated phenotypes provided by the GAW19 organizers. For the single-step approach, power of the gene-based tests on a particular causal gene is estimated as the proportion of the 200 simulated phenotypes for which that gene is significant (significance levels discussed below).
For the multistep approach, we first report a similar empirical estimate for power of the pathway-based tests: the proportion of the 200 simulated phenotypes for which a pathway containing at least 1 causal gene (causal pathway) is significant. We also report the proportion of times a causal gene and the pathway in which it is contained are both significant.
Type I error estimates are calculated very similarly. Estimates are achieved by running tests with the variable Q1 as the response. Q1 was simulated by the workshop organizers so as to not be associated with any genes, so we can estimate type I error as the proportion of the simulated phenotypes for which a gene or pathway is significantly associated with Q1.
Initially, we evaluate significance using conventional genome-wide association study alpha levels that penalize for multiple testing: 10−6 for single-step approach gene-based tests, 5 × 10−4 for multistep approach pathway tests, and 0.05 divided by the number of genes within each pathway for multistep approach gene-based tests. Because of very low observed power with these conservative significance levels (see “Results” below for details), we also consider more liberal alpha levels (0.005 for the single-step approach gene tests, 0.05 for multistep approach pathway tests, and 0.05 for multistep approach gene tests) to facilitate identification of causal variant-sets.
Single-step approach: power and type I error of gene-based approach
Using a conventional genome-wide association study alpha level that corrects for multiple testing across all genes (10−6), we find that both VC test and Burden test are severely underpowered on this data set. Only 1 gene, MAP4, which has the strongest effects on SBP and DBP in the GAW19 simulated data, has reasonable power (0.7), and nearly all other genes containing causal variants have little to no power (detailed results not provided). When a more liberal alpha level is used (0.005), power increased above the nominal type I error rate for many genes (detailed results not shown). The top 2 most powerful genes for VC test were MAP4 (VC test and Burden test power = 1) and SCAP (VC test power = 0.97, Burden test power = 0), while the top 2 hits for Burden test were MAP4 and FLT3 (Burden test power = 0.31, VC test power = 0). Modest power for these and a handful of other genes containing causal variants was not at the expense of control of the type I error rate. In particular, Q1 (a simulated variable not associated with genotypes useful for assessing type I error rates) yielded a well-controlled type I error rate (VC test Mean = 0.003; SD = 0.004; Burden test Mean = 0.006, SD = 0.006) across the 245 genes containing at least 1 causal variant.
Multistep approach: power and type I error of pathway-based approach
First step: pathway-based association tests
Power comparisons in the previous paragraph benefit both from a larger significance level (0.05 vs. 0.005) and some lack of granularity in what the results tell the researcher (pathway significance vs. gene significance). In particular, Step 1 does not indicate which variant (s)/gene (s) are significant within the pathway. In the next section, we explore power results considering Step 2 of the multistep approach.
Second step: gene-based association tests
Comparison of power for genes showing at least a 10 percentage point increase in power for multistep pathway analysis
Number of genes
Burden test -Burdentest
Burden test -VCtest
We propose a general framework for conducting pathway analysis on family-based data for rare variants. Current pathway-based and gene-based variant-set testing methods are severely underpowered using standard genome-wide association study significance levels on this data set. However, when more liberal significance levels are used, the novel multistep approach proposed here shows generally increased power over conventional single-step testing approaches. We notice even larger improvements in power when we follow up a pathway test with a similar gene-based test (VC test -VC test and Burden test -Burden test ). This makes sense when we consider that in these cases the genetic architecture (eg, signal) being looked for at both stages is the same. We anticipate seeing similar patterns on other data sets with better power and using standard significance levels, though application of the proposed methods to other data sets is necessary to confirm this.
Importantly, if current methods were modified to provide better control of the multistep type I error rate (instead of being overly conservative) it is possible that the difference in the power of 2 methods would be even greater. However, it is important to note that multistep type I error and power will always be less than or equal to single-step type I error if the same significance level is used in both cases. However, typically, different significance levels will be appropriate as the number of genes under consideration is typically more than the number of pathways.
Our current work is limited in a number of ways including: (a) It was evaluated on a single data set with simulated phenotypes, (b) it only uses single-stage pathway association tests (single test of all variants in a pathway instead of testing each gene first, and then aggregating; see Introduction for details), (c) it incorporates common variants instead of excluding them, (d) it uses a theoretical kinship matrix, and (e) it only evaluates method performance using synthetic pathways. These are all areas for further research, but would not be difficult to incorporate into the current, flexible framework of our approach.
Finally, there were a handful of cases where the single-step (gene-based approach) was better than the multistep approach. This was generally when pathways contained very few other causal genes and/or causal genes with small effect sizes. Consideration of multistep methods that are more robust to the inclusion of noncausal genes may help limit potential power loss in these cases. Further work is necessary.
A novel multistep pathway approach showed improved power versus single-step approaches for most genes across a wide variety of scenarios. Further work is needed to evaluate the robustness of these findings across a wider range of complex disease architecture.
This work was funded by the National Human Genome Research Institute (R15HG006915). We acknowledge the use of the Hope College parallel computing cluster for data analysis, and Dordt College and its Summer Research Program in Statistical Genetics for their continued support. The GAW19 whole genome sequence data were provided by the Type 2 Diabetes Genetic Exploration by Next-generation sequencing in Ethnic Samples (T2D-GENES) Consortium, which is supported by National Institutes of Health (NIH) grants U01 DK085524, U01 DK085584, U01 DK085501, U01 DK085526, and U01 DK085545. The other genetic and phenotypic data for GAW19 were provided by the San Antonio Family Heart Study and San Antonio Family Diabetes/Gallbladder Study, which are supported by NIH grants P01 HL045222, R01 DK047482, and R01 DK053889. The Genetic Analysis Workshop is supported by NIH grant R01 GM031575.
This article has been published as part of BMC Proceedings Volume 10 Supplement 7, 2016: Genetic Analysis Workshop 19: Sequence, Blood Pressure and Expression Data. Summary articles. The full contents of the supplement are available online at http://bmcgenet.biomedcentral.com/articles/supplements/volume-17-supplement-2. Publication of the proceedings of Genetic Analysis Workshop 19 was supported by National Institutes of Health grant R01 GM031575.
All authors contributed to the design of the study and early data processing steps. AV and KG conducted analyses, implemented the method and drafted the manuscript. NT revised the manuscript. AV and KG contributed equally to this work. All authors read and approved the final manuscript.
The authors declare they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Liu K, Fast S, Zawistowski M, Tintle NL. A geometric framework for evaluating rare variant tests of association. Genet Epidemiol. 2013;37(4):345–57.View ArticlePubMedGoogle Scholar
- Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, Christiani DC, Wurfel MM, Lin X. Optimal unified approach for rare-variant association testing with application to small-sample case–control whole-exome sequencing studies. Am J Hum Genet. 2012;91(2):224–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):82–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Li B, Leal SM. Methods for detecting associations with rare variants for common diseases : application to analysis of sequence data. Am J Hum Genet. 2008;83(3):311–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Juraeva D, Haenisch B, Zapatka M, Frank J, Witt SH, Mühleisen TW, Treutlein J, Strohmaier J, Meier S, Degenhardt F, et al. Integrated pathway-based approach identifies association between genomic regions at CTCF and CACNB2 and schizophrenia. PLoS Genet. 2014;10(6), e1004345.View ArticlePubMedPubMed CentralGoogle Scholar
- Greco B, Luedtke A, Hainline A, Alvarez C, Beck A, Tintle NL. Application of family-based tests of association for rare variants to pathways. BMC Proc. 2014;8 Suppl 1:S105.View ArticlePubMedPubMed CentralGoogle Scholar
- Goeman JJ, van de Geer SA, De Kort F, Van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics. 2004;20(1):93–9.View ArticlePubMedGoogle Scholar
- Pedroso I, Breen G. Gene set analysis and network analysis for genome-wide association studies. Cold Spring Harb Protoc. 2011;2011:9.View ArticleGoogle Scholar
- Zhu Y, Xiong M. Family-based association studies for next-generation sequencing. Am J Hum Genet. 2012;90(6):1028–45.View ArticlePubMedPubMed CentralGoogle Scholar
- PLINK. http://pngu.mgh.harvard.edu/~purcell/plink/. Accessed 15 Aug 2014.
- GenGen. http://www.openbioinformatics.org/gengen/. Accessed 15 Aug 2014.
- Shugart YY, Zhu Y, Guo W, Xiong M. Weighted pedigree-based statistics for testing the association of rare variants. BMC Genomics. 2012;13:667.View ArticlePubMedPubMed CentralGoogle Scholar
- Blangero J, Teslovich TM, Sim X, Almeida MA, Jun G, Dyer TD, Johnson M, Peralta JM, Manning A, Wood AR, Fuchsberger C, Kent Jr JW, et al. Omics-squared: Human genomic, transcriptomic and phenotypic data for Genetic Analysis Workshop 19. BMC Proc. 2015;9(8):S2.Google Scholar
- Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med. 2005;24(19):2911–35.View ArticlePubMedGoogle Scholar
- Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension. 2002;41(2):207–10.View ArticleGoogle Scholar
- Pugh E. Personal communication. 2014.Google Scholar
- Voorman A, Brody J, Lumley T. skatMeta: Efficient meta-analysis for the SKAT test. 2013. https://cran.r-project.org/web/packages/skatMeta/index.html. Accessed 15 Aug 2014.Google Scholar